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1. Introduction 
Retinoblastoma is a malignant embryonal tumour of childhood arising at the expense of 
retinal cones. It has an incidence of 1 per 15,000 to 20,000 births. In 90% of cases, it is 
diagnosed before the age of 3 years. The possibility of conservative management depends 
on early diagnosis (Moll et al., 1996). However, although treatment strategies have advanced 
considerably, the visual prognosis is still a major source of concern, especially central vision 
when the tumour is situated at or close to the macula. In two-thirds of cases, the lesion is 
unilateral and the median age of diagnosis is 2 years. In the other third, the lesion is bilateral 
and the disease is diagnosed earlier, possibly even during the neonatal period, with a 
median age of diagnosis of 1 year. Most cases of unilateral and bilateral retinoblastoma are 
sporadic, with no family history. However, 10 to 15% of all cases of retinoblastoma present a 
family history. The distribution of cases within the family is compatible with the existence of 
a tumour susceptibility gene transmitted according to an autosomal dominant mode with 
high penetrance. In this case, the lesion is usually bilateral and diagnosed at an early age. 
1.1 Diagnosis 
The most frequent presenting signs are leukocoria (white pupillary reflex) and strabismus. 
Retinoblastoma may also be discovered on routine ocular fundus examination performed in 
a child from a high-risk family. 
The diagnosis is essentially based on the ocular fundus examination under general 
anaesthesia, completed by ultrasound and CT. Tumour growth may be endophytic with 
invasion of the vitreous cavity or, more rarely, exophytic with retinal detachment. A precise 
description of the lesions based on fundoscopy findings allows the lesion to be classified 
according to the 5 stages of the Reese-Ellsworth classification, associated with an 
increasingly severe prognosis. Ultrasound and orbital CT demonstrate tumour calcifications 
www.intechopen.com
Retinoblastoma – An Update on Clinical,  
Genetic Counseling, Epidemiology and Molecular Tumor Biology 
 
56
highly suggestive of retinoblastoma and CT contributes to staging in advanced forms. In the 
case of enucleation, the diagnosis and staging are confirmed by histological criteria. 
Conservative treatment must be attempted whenever possible: chemotherapy, radiotherapy, 
photocoagulation, and cryotherapy. Very advanced forms unsuitable for conservative 
treatment will require enucleation. This treatment is still unfortunately often required for 
sporadic retinoblastomas whose diagnosis is made late. 
1.2 Predisposition to retinoblastoma 
In 1971, Knudson proposed a model designed to explain why most familial retinoblastomas 
were bilateral and occurred at an early age and, inversely, why unilateral cases were usually 
isolated and diagnosed later (Knudson, 1971). He proposed the hypothesis that two 
mutations of key genes in the control of cell division occurring in a retinal neuroectodermal 
cell were necessary, but possibly not sufficient, for development of retinoblastoma. In 
bilateral forms, the first mutation is a germline mutation, present in all cells of the body and 
especially in all retinal neuroectodermal embryonal cells, while the second mutation is 
somatic, acquired during foetal life or the first months of neonatal life. Although the 
probability of two somatic mutations in two key genes in the same retinal cell is extremely 
low, development of a single mutation is not a rare event and induces development of a 
retinoblastoma when another mutation is already present. This explains why children with a 
germline mutation have a high risk of developing not just one, but two or more tumours. 
Comings completed Knudson’s hypothesis in 1973 by postulating that the two mutations 
necessary for the development of retinoblastoma corresponded to inactivation of the two 
alleles of the same gene, that had not yet been identified at that time (Comings, 1973). The 
hypothesis of the existence of tumour suppressor genes, already suspected, became very 
likely. 
In familial cases, the germline mutation is transmitted by one of the parents. In sporadic, 
bilateral and sometimes multifocal unilateral cases, the germline mutation usually 
corresponds to a de novo mutation arising in the gametes of one of the two parents (pre-
zygotic) or at an early stage after fertilization (post-zygotic). Pre-zygotic de novo mutations 
are associated with advanced paternal age. In some cases, the apparently sporadic nature of 
retinoblastoma is related to incomplete penetrance in one carrier parent. As the risk of 
tumour is high, but incomplete, a parent with a germline mutation may fail to develop 
retinoblastoma during childhood or may have developed a spontaneously regressive 
retinoblastoma, which may leave a retinal scar or retinoma. It is therefore very important to 
perform an ocular fundus examination in each parent looking for retinoma, which would 
reveal a previously unknown family history that would consequently modify genetic 
counseling. This point is discussed in more detail in the “Notes” section of the chapter on 
“Genetic counseling”. 
Most unilateral cases are due to two mutations occurring only at the somatic level. 
However, it is estimated that almost 10% of patients with unilateral retinoblastoma have a 
germline mutation. 
A risk of cancer different of retinoblastoma exists within retinoblastoma predisposition. 
Rare patients develop pineal region tumour but is considered like an ectopic intracranial 
retinoblastoma and so-called trilateral retinoblastoma. An increased risk of second cancers 
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for RB1 mutation carriers, after retinoblastoma, is well documented. In childhood and early 
adulthood, these patients have a high incidence of osteosarcomas and soft tissue sarcomas. 
The incidence of these cancers can often be attributed to external beam radiation therapy, 
but many cases have been reported occurring outside of the field of radiation treatment and 
even for patients who received no radiation. A cumulative rate of second cancers is reported 
18 years after the diagnosis of genetic retinoblastoma at 8.4% (and 6% for osteosarcomas 
alone) (Draper et al., 1986). Otherwise, RB1 mutation carriers have also a high lifetime risk 
of developing a late onset epithelial cancer (lung, bladder, breast) and melanoma. In a 
historic series of 144 survivors of hereditary retinoblastomas, the cumulative cancer 
incidence to 85 years of age has been estimated to be 68.8% (CI= 48.0% to 87.4%) (Fletcher et 
al., 2004). 
1.3 The RB1 gene 
The identification, in 1963, of germline deletions of chromosome 13 (then considered to be a 
group D chromosome) in rare patients with bilateral retinoblastoma and presenting mental 
retardation and a dysmorphic syndrome suggested that the retinoblastoma susceptibility 
gene was localized in this chromosomal region (Baud et al., 1999, Lele et al., 1963). 
Comparative analysis of highly polymorphic germline and tumour genetic markers 
localized in 13q14 subsequently demonstrated loss of heterozygosity in about 65% of 
tumours. In other words, in more than one half of tumours, the susceptibility gene is altered 
in somatic cells by complete loss of the chromosomal region in which it is localized. It has 
also been demonstrated that, in familial forms of retinoblastoma, the remaining allele in the 
tumour was always the allele common to all affected members of the family, i.e. the allele 
carrying the predisposition to retinoblastoma. Analysis of a large number of retinoblastomas 
identified the smallest common region of deletion in 13q14, which allowed research to be 
focussed on this region. In 1986, identification of a gene localized in the region of interest 
and constituting a site of inactivating germline mutations in children with bilateral 
retinoblastoma confirmed that this gene corresponded to the retinoblastoma susceptibility 
gene; it was called RB1(Friend et al., 1986). Identification of RB1 confirmed the 
complementary hypotheses of Knudson and Comings, opened the way to cancer 
susceptibility gene testing and allowed definition of the risk of retinoblastoma within 
particular families. 
The RB1 gene codes for a 110 kD nuclear protein with an ubiquitous expression, which, 
together with proteins p107 and p130, belongs to the pocket protein family. These proteins 
share in common a domain corresponding to a highly conserved region, the pocket domain, 
which allows sequestration of transcription factors, such as those of the E2F family. During 
the G1/S transition of the cell cycle, the pRB protein binds to E2F factors and suppresses 
their activity, consequently blocking progression to S phase. Inversely, phosphorylation of 
pRB releases E2F factors, allowing completion of the cell cycle. The pRB protein is involved 
not only in regulation of the cell cycle, but also in control of termination of cellular 
differentiation and in exit of the cell from the cell cycle during development. It appears to 
interact with more than 100 different proteins (Zhu, 2005, Classon&Harlow, 2002, 
Chau&Wang, 2003, Bremner et al., 2004). It is probably this role in differentiation which 
explains the spatiotemporal specificity of the tumour risk associated with RB1 gene 
mutations and consequently damage to retinal neuroectodermal cells during early 
childhood. 
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2. Genetic counseling protocols 
2.1 Overview 
Whenever unilateral or bilateral retinoblastoma is diagnosed in a child, it is important to 
consider the possibility of a genetic predisposition and therefore the risk of development of 
the disease in young children related to the patient. 
Analysis of the family history and the tumour history of a patient treated for retinoblastoma 
is essential to evaluate the possibility of a genetic predisposition and the risk of 
development of the disease in other members of the child’s family and to guide the 
ophthalmological surveillance of family members (siblings, cousins or offspring). It is 
therefore possible to calculate the probability of relatives of a child with retinoblastoma to 
present a genetic predisposition to this disease. These calculations are based on the 
following elements: (1) 100% of patients with bilateral retinoblastoma and 10% of patients 
with unilateral retinoblastoma are considered to present a genetic predisposition, (2) the 
mode of transmission is dominant; a carrier parent therefore has once chance in two of 
transmitting the susceptibility gene to each child, (3) the penetrance is 90% at birth, which 
means that an adult who did not develop retinoblastoma in childhood has a tenfold lower 
probability of being a carrier compared to the probability at birth (Figure 1). 
Based on comparative analysis of the various approaches to ophthalmological surveillance 
in different countries and our multidisciplinary experience at Institut Curie, we can propose 
guidelines for the surveillance of relatives of patients followed for retinoblastoma (Figure 1) 
(Abramson et al., 1998, Moll et al., 2000, Musarella&Gallie, 1987). The modalities of this 
surveillance depend on the probability of predisposition of the child to be followed, which 
depends on the child’s age and degree of kinship with the affected child, and on the age 
distribution at diagnosis in predisposed children followed since birth. In a series of 50 
predisposed children followed since birth, the diagnosis of retinoblastoma was established 
before the age of 6 months in 80% of cases, before the age of 18 months in 92% of cases and 
at the age of 4 years in one case. Finally, even for the lowest levels of risk for which 
ophthalmological surveillance is recommended, ocular fundus examination must be 
performed at least every 3 months until the age of 24 months in order to ensure effective 
prevention. These surveillance guidelines are very rigorous: ocular fundus examination at 
the first month of life, or even the first week, in a specialized unit, with frequent follow-up 
examinations requiring general anaesthesia from the second or third examination. For 
example, in the case of a 50% risk of being a carrier (a child born to a patient with bilateral 
retinoblastoma), surveillance starts at the first week of life, and then once a month until the 
age of 18 months (Figure 1). 
These guidelines must be maintained in the absence of genetic testing or while waiting for 
the results, as genetic testing in all patients with unilateral or bilateral retinoblastoma, 
followed by testing of the relatives, can eliminate the need for surveillance of a certain 
number of children, depending on the results. 
2.2 Counseling 
Molecular genetic studies of the RB1 gene can now be proposed to all patients with familial 
or sporadic unilateral or bilateral retinoblastoma. Genetic testing must be performed in the 
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Fig. 1. Ophthalmological surveillance guidelines 
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context of a genetics consultation in collaboration with the ophthalmology, paediatric 
oncology and radiotherapy teams managing the child. During this consultation, the patient’s 
pedigree is built looking for other tumour cases in the family and especially other 
retinoblastoma cases. Patient or parents of young patients are informed about 
retinoblastoma predisposition. Ocular fundus examination of parents is required to search 
for retinoma which would reveal a previously unknown family history. Follow up of young 
patient’s relatives by ocular fundus is recommended. Blood sampling for RB1 molecular 
analysis is proposed to search for germline mutation. Finally, an informed consent has to be 
signed by the patients or their legal guardians if RB1 screening is accepted. Following RB1 
screening, results are delivered during another genetic consultation. The printed test results 
are given to the parents and are also kept by the genetics department for at least thirty years, 
so that they can be consulted by the child during early adulthood. Today, a first-line 
screening for the two inactivating somatic mutations in the tumor DNA (when available) is 
performed and represents an attractive alternative: identification of these mutations only in 
the tumour and not in the leukocytes of the patient eliminates the risk of recurrence in 
siblings and cousins (see below). 
The assessment usually starts with molecular genetic testing but cytogenetic analysis is 
performed as first-line procedure in the case of associated mental retardation or 
characteristic dysmorphic syndrome. 
2.3 Clinical management/surveillance (Figure 2) 
When a mutation has been demonstrated in an affected child, genetic testing based on 
screening for this mutation, is recommended for the siblings. Ophthalmological surveillance 
can be stopped in a relative when genetic testing fails to reveal the mutation identified in the 
family. Genetic testing is also proposed to the parents. If one of the two parents carries the 
mutation, antenatal diagnosis may be proposed for a subsequent pregnancy. If the parents 
do not carry the mutation, their respective families can be reassured, eliminating the need 
for ophthalmological surveillance of the patient’s cousins. In contrast, it is impossible to 
assess the level of representation of the mutation identified in the affected child in the 
gametes of the parent in which a de novo mutation has occurred (quantification of the 
germline mosaic), or, in other words, it is impossible to eliminate the risk of recurrence in 
the siblings of the affected child. In this case, for each new birth in the immediate family, a 
genetic test must be proposed during the neonatal period. Antenatal diagnosis can be 
proposed case by case. 
When no RB1 gene mutation is demonstrated in the affected child: 
1. In the case of bilateral retinoblastoma, genetic screening techniques have certain 
limitations and may fail to demonstrate a mutation, in which case surveillance of the 
patient’s relatives must be continued (Figure 1). Somatic mosaics may also be 
observed, as an alteration of the RB1 gene can occur in the patient during embryonic 
development and may not be present in leukocyte DNA. If the mutation is present in 
the germline, this patient may transmit the mutation to his/her offspring. It is 
currently proposed to repeat RB1 gene testing at the birth of each child of a patient 
with a history of bilateral retinoblastoma in childhood in whom molecular RB1 gene 
testing was negative. 
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Fig. 2. Clinical management/surveillance 
2. In the case of unilateral sporadic retinoblastoma, the genetic counsellor can be more 
reassuring, as the risk of a genetic predisposition is very low (1% instead of 10%, taking 
into account a 90% screening sensitivity, see below). However, once again, certain 
limitations of the techniques used and the risk of somatic mosaic must be kept in mind. 
It is therefore recommended to continue ophthalmological surveillance in the patient’s 
offspring (Figure 1). However, if the probability of predisposition of a child with 
unilateral retinoblastoma is only 1%, the risk for his nephews is around 0,00125% or 
1/80 000 i.e. lower than in the general population. As a result their ophtalmologic 
follow-up should be stopped. 
3. In familial forms comprising two accessible cases, indirect genetic testing rapidly 
demonstrates the mutant allele of the RB1 gene. This method can then be used to 
detect relatives with the cancer-predisposing allele and allows the possibility of 
antenatal diagnosis. Indirect molecular genetic testing can also be proposed for 
families with only one case of retinoblastoma, while waiting for the results of RB1 
screening or when no mutation is detected. The objective in this setting is to suspend 
surveillance of a child not sharing any RB1 allele in common with its brother or sister 
with retinoblastoma, i.e. in one case in four, or even one case in two when loss of 
heterozygosity is demonstrated in the patient’s tumour, designating the remaining 
allele as the putative predisposing allele. It should be stressed that even when a child 
shares an allele in common with the patient, the probability that he or she has an RB1 
gene mutation remains very low (Figure 1). However, as a precaution, 
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ophthalmological surveillance should be continued. Antenatal diagnosis cannot be 
considered in this particular setting. 
2.4 Notes 
For a long time, it was considered that all patients with a deleterious RB1 gene mutation 
developed retinoblastoma regardless of the type of molecular lesion. However, the risk 
within a given family has now been clearly established to be heterogeneous, as some 
members do not develop retinoblastoma, while others develop bilateral retinoblastoma, or 
even a secondary tumour. The severity of the risk can be evaluated by the disease-eye-ratio 
(DER), which is a good marker of penetrance and level of expression (Lohmann et al., 1994). 
The DER is the ratio of the number of eyes affected over the number of carriers within the 
family. One of the problems of genetic counseling for retinoblastoma is therefore to evaluate 
the tumour risk for an unborn child with a germline RB1 gene mutation, hence the 
importance of developing our knowledge of genotype-phenotype relationships. 
In general, subjects with a mutation in the first generation may have an attenuated 
phenotype due to a possible mosaic. The type of lesion then varies according to the type of 
mutation (Lohmann&Gallie, 2004, Harbour, 2001, Taylor et al., 2007). 
Subjects with a mutation leading to a truncated protein (stop, frameshift) have a high risk, 
greater than 90%, of bilateral retinoblastoma (mean DER = 1.85). Of note, some truncating 
mutations in exon 1 may lead to low-penetrance retinoblastoma trough alternative 
translation initiation (Sanchez-Sanchez et al., 2007). The situation is more complex for the 
other types of mutations, as discussed below. 
Splicing mutations are associated with a lower mean DER (1.5) and, in some cases, with high 
intrafamily variability with the presence of tumour-free and bilateral cases in the same 
family. The variability of the DER is mainly due to maintenance of the frame and/or the 
respect of functional domains. The case of IVS06+1G>T splicing mutation is quite 
remarkable, as this mutation is supposed to result in a skip of exon 6 out of phase and 
therefore in the absence of protein, as the truncated messenger is eliminated by Non sense 
Mediated Decay (NMD) (Holbrook et al., 2004). This mutation is actually associated with an 
extraordinary variability of intrafamily and interfamily penetrance. The mechanisms 
proposed to account for this phenomenon are maintenance and therefore translation of the 
truncated messenger, possibly related to a parental effect (Klutz et al., 2002) or 
overexpression of the wild-type allele, resulting in a normal level of RB1 expression (Taylor 
et al., 2007). 
Anomalies of the promoter region are classically associated with variations of the level of 
expression of the messenger and result in variable but generally low DER. 
Missense mutations are very rare. When they do not alter splicing (see above), they can be 
responsible for a partially functional protein (e.g. R661W), which results in a very low mean 
DER (0.3), but the possibility of bilateral cases cannot be excluded (Onadim et al., 1992). 
Chromosomal rearrangements (deletion or duplication of one or several exons, or even the 
whole gene) are associated with a variable DER (mean: 1.4), particularly and surprisingly, 
deletions comprising all of RB1, for which the phenotype can vary from no lesion to bilateral 
retinoblastoma (Albrecht et al., 2005). 
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The type of mutation therefore affects the type of lesion, but modifying factors influencing 
splicing, the level of expression and/or cell survival also appear to be involved. As an 
example, the existence of these genetic modifiers in retinoblastoma have been suspected and 
searched in the pRB or p53 pathways in which MDM2 is a key regulator of both p53 and 
pRB catabolism. We have recently demonstrated that the minor allele of MDM2 that 
includes a 309T>G transversion (SNP rs2279744) in the MDM2 promoter is strongly 
associated under a recessive model with incidence of bilateral or unilateral retinoblastoma 
among members of retinoblastoma families (Castéra et al., 2010). 
In the context of genetic counseling, the possibility of antenatal or even pre-implantation 
diagnosis can be proposed to couples with a 50% risk of transmitting an RB1 gene mutation. 
The situation is obviously more delicate in families presenting an intrafamily heterogeneous 
risk, which makes genetic counseling more difficult. Although it appears impossible to 
reassure a parent with no history of retinoblastoma, but carrying an RB1 mutation about the 
tumour risk for his/her offspring, it is very difficult to inform this subject about techniques 
allowing the birth of a mutation-free infant. It is therefore very important to continue the study 
of these families in order to improve genetic counseling in the context of retinoblastoma. 
3. Molecular methods in genetic testing 
3.1 Overview 
The molecular pathology of RB1 is very diverse and about 500 distinct germline mutations 
have been described to date, some of which are listed in two databases managed by  
Dr Lohmann (http://RB1-lsdb.d-lohmann.de) and Dr Pestaña (http://www.es.embnet.org/ 
Services/MolBio/rbgmdb). These mutations occur throughout the coding sequence and in 
the promoter region with the notable exception of the last 2 exons (figure 3). Most of these  
 
RB1 coding sequence is drawn to scale, and exons shown in grey are part of pocket domains A or B. 
Large deletions are represented as black lines. 
Fig. 3. Pattern of mutations found in a series of  192 retinoblastoma patients (adapted from 
Houdayer et al., 2004) 
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mutations are de novo mutations. The spectrum of germline mutations mainly comprises 
nonsense mutations (about 40%), frameshift insertions or deletions of several bases (about 
25%), altered splicing (about 20%) and chromosomal rearrangements, i.e. 
deletions/duplications of one or several exons, or even the entire gene (about 10%). The 
remaining mutations correspond to rare missense mutations and mutations of the 
promoter region. Variations of the relative proportions of these mutations have been 
reported, which can be explained by differences of the population studied, and 
environmental or stochastic factors, related to the high rate of de novo mutations 
(Dehainault et al., 2004, Alonso et al., 2001). Finally, constitutional inactivation of RB1 can 
be due to exceptional cases of chromosomal rearrangements only visible on cytogenetics 
(e.g. translocations, inversions). These same types of alterations are also found in the 
tumour, as well as hypermethylation of the promoter region and large chromosomal 
losses comprising all of RB1 and flanking regions (Richter et al., 2003).Tumoral events are 
now systematically searched when the tumor is available. 
3.2 Materials 
Analysis of the index case, which requires a larger amount of material, must be 
distinguished from that of relatives, in whom the search for a previously identified mutation 
requires less material. 
3.2.1 Study of the index case 
Testing for germline RB1 gene mutations is classically performed on DNA extracted from 
whole blood collected on EDTA. Two to 3 µg of genomic DNA are required for screening for 
point mutations and large mutations on the entire gene. Extraction can be performed with 
commercial kits or by phenol/chloroform or perchlorate/chloroform or salting out 
techniques (Johns&Paulus-Thomas, 1989, Miller et al., 1988). 
When DNA is used for screening, RNA must also be available due to the frequency of 
splicing alterations. RNA analysis may be essential to demonstrate the impact of the 
presumptive mutation identified on genomic DNA. RNA is obtained from a blood sample 
collected on heparin, Acid Citrate Dextrose (ACD), or EDTA. Lymphoblastoid cell culture is 
an interesting option, as it provides an infinite source of nucleic acids, but it is expensive 
and requires cell culture facilities. 
Finally, tumour DNA analysis is important for the molecular diagnosis of retinoblastoma. 
Samples fixed in Bouin’s solution cannot be used, as this fixative degrades DNA, and frozen 
blocks are preferable to paraffin-embedded blocks. When the first-line analysis is performed 
on the tumour (see below), a sufficient amount of material must be available (2 to 3 µg). A 
small quantity is sufficient when looking for a known mutation and it is even possible to 
obtain genetic material by scratching a slide. Tumour DNA can be extracted with 
commercial kits or phenol/chloroform. 
3.2.2 Study of relatives 
In this setting, genetic testing is designed to detect a previously identified mutation, and a 
small quantity of DNA is sufficient (about 50 ng) and can be extracted from buccal cells 
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collected by swabbing, a simple, noninvasive technique. FTA technology (Gaytmenn et al., 
2002, Seah et al., 2003) is then the preferred method: swabs are applied onto FTA cards, 
buccal cells are then lysed and nucleic acids are immobilized and stabilized in the FTA 
matrix. The paper support is then punched out and the punch is washed and placed in the 
PCR reaction tube. Alternatively, buccal cells can be extracted from the swab by using 
standard commercial kits. 
3.3 Methods 
There are two types of diagnostic genetic molecular testing: direct testing and indirect 
testing. 
3.3.1 Direct testing 
Direct testing consists of looking for a germline alteration of the RB1 gene indicative of a 
predisposition to retinoblastoma. The first study performed in a family is time-consuming 
and generally takes several months. In contrast, when testing is performed to detect a 
mutation already identified in the family, targeted screening of the previously identified 
mutation takes only a few days. Direct testing is essentially performed on blood samples. It 
is good practice to verify the presence of a mutation on two DNA samples obtained 
independently: two blood samples taken at two different times, or a blood test and a buccal 
swab. 
Direct testing can also be performed on the tumour. This screening can be very useful in 
bilateral cases in which no mutation is detected on leukocytes, but also for unilateral forms, 
as identification of a mutation only in the tumour would be very useful for genetic 
counselling, eliminating the risk of recurrence in siblings and cousins (but not in the 
offspring). Testing of tumour DNA is obviously subject to availability of material, i.e. 
enucleation. 
The complexity of the mutational spectrum of the RB1 gene requires analysis of the entire 
coding sequence and promoter region by several complementary techniques (see DNA 
methylation analysis). 
3.3.1.1 Detection of point mutations 
Point mutations are usually investigated by Denaturing High Performance Liquid 
Chromatography (Xiao&Oefner, 2001, Dehainault et al., 2004) and/or direct DNA 
sequencing (Richter et al., 2003), or even Denaturing Gradient Gel Electrophoresis (which is 
more complicated to perform) (Fodde&Losekoot, 1994) or Single Strand Conformational 
Polymorphism (low sensitivity) (Orita et al., 1989). Recently, we have adapted a novel HDA 
method (Houdayer et al., 2010) called Enhanced Mismatch Mutation Analysis (EMMA). 
Regardless of the technique used, the gene is cut into amplicons corresponding to the exon 
sequence and intron/exon junctions in order to detect any abnormalities of splicing 
consensus sequences which can have major functional consequences. 
DHPLC is an adaptation of high performance liquid chromatography for DNA applications, 
used for the detection of point mutations. It is based on the principle of physical separation, 
under denaturing conditions, of various DNA fragments in a mobile phase by differential 
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retention on a solid phase composed of a DNA column. DHPLC has a high sensitivity, 
making it a very useful tool in retinoblastoma for the study of tumours or mosaics, which 
are not uncommon. DHPLC is able to detect less than 20% of the minority allelic species, 
which corresponds to the accepted limit for sequencing. The limitations of DHPLC depend 
on the base composition of the DNA fragment studied (see “Notes” section). 
EMMA is based on the use of innovative matrices increasing the electrophoretic mobility 
differences between homoduplex and heteroduplex. DNA Sensitivity is further improved by 
using nucleosides as additives to enhance single-base substitution detection. Nucleosides 
are expected to interact with mismatched bases of heteroduplexes, thereby increasing 
mobility differences with homoduplexes. Moreover, this method, in combination with 
adapted semiquantitative PCR conditions, can be used to simultaneously detect point 
mutations and large-scale rearrangement in a single run (Weber et al., 2006, Weber et al., 
2007). This feature, combined with the use of a single set of separation conditions for all 
fragments and with the multiplexing capability of the method, leads to a considerable 
simplification and cost reduction compared to previous methods (Caux-Moncoutier et al., 
2010). 
Direct sequencing is the second option and is considered to be the reference technique. 
However, its performances are highly dependent on the apparatus, chemistry, polymers and 
software used. A study comparing DHPLC and direct sequencing for BRCA1 analysis 
concluded on a similar detection rate for the two techniques (Alonso et al., 2001). 
Direct testing is also performed on RNA to characterize any abnormal splicing. Classically, 
after extraction of RNA and RT PCR, the cDNA region surrounding the putative anomaly is 
amplified to demonstrate abnormal transcripts. The instability of messenger RNA carrying a 
premature stop codon, or NMD (Holbrook et al., 2004), constitutes a real problem in 
diagnostic molecular genetics and is discussed in the “Notes” section. 
3.3.1.2 Detection of chromosomal rearrangements 
Chromosomal rearrangements, i.e. deletion/duplication of one or several exons, cannot be 
detected by the techniques used to detect point mutations because the mutant allele is 
masked by the wild-type allele, as the retinoblastoma susceptibility gene segregates 
according to an autosomal dominant mode. 
Specific gene assay techniques must be used in order to distinguish 2 copies of the target 
(wild-type status), one copy (deletion) or 3 copies (duplication). Semiquantitative 
techniques, such as Quantitative Multiplex PCR of Short fluorescent Fragments (QMPSF), 
Multiplex PCR/liquid chromatography assay (MP/LC) (Duponchel et al., 2001, Dehainault 
et al., 2004),  and Multiplex Ligation Probe Amplification (MLPA) (Schouten et al., 2002) or 
quantitative techniques, i.e. real-time PCR, are used. QMPSF is a technique allowing 
simultaneous, semiquantitative amplification of several exons; the intensity of the signal 
obtained therefore depends on the number of copies of the gene of interest in the matrix 
DNA. After amplification of the exons followed by separation of the PCR products obtained 
by electrophoresis, the patient electrophoretograms are compared to those of normal and 
mutant controls. The signal intensity in the various samples is then evaluated and deletions 
of one or several amplicons are revealed by a 50% reduction of the corresponding peak(s). 
Data can be exported to an Excel spreadsheet and analysed by a macro. The advantage of 
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QMPSF and other semiquantitative multiplex PCR approaches is their high throughput and 
the small number of analytical steps, which is always appreciated in the diagnostic setting. 
Another widely used semiquantitative technique, MLPA, is based on a step of hybridization 
of specific probes, fitted with a universal tail, and corresponding to the exons to be 
examined. The quantity of probe hybridized is therefore proportional to the quantity of 
target. After hybridization and ligation, probes are then amplified by PCR with a set of 
universal primers and PCR products are separated be capillary electrophoresis. Once again, 
the signal intensity, compared to that of normal and mutant controls, is used to detect 
chromosomal rearrangements. Despite a much higher multiplexing capacity, the throughput 
of MLPA is lower than that of semiquantitative multiplex PCR approaches due to an 
additional analytical step (ligation), but the advantage of this technique is that it is available 
in the form of ready-for-use kits for many genes including RB1. 
These two approaches have similar performances and the choice between the two therefore 
depends on the user’s priorities. 
Real-time PCR techniques are particularly suitable for gene assays. They are based on either 
i) incorporation of a free fluorophore (typically SYBR Green) into the forming strands, 
which generates an increase in the intensity of fluorescence with the number of copies 
produced. The sensitivity of these techniques is enhanced by the use of fluorophore-labelled 
specific probes. Unfortunately, they have a low throughput, limited by the number of 
fluorophores available and are therefore not widely used for screening, especially as this 
low throughput is not justified by the gain in sensitivity. 
An approach combining the search for point mutations and chromosomal rearrangements 
achieves a germline RB1 gene mutation detection rate of about 90% among patients with 
bilateral retinoblastoma (Richter et al., 2003). The mutations that are not detected are 
probably deep intronic anomalies, responsible for alternative splicing defects that are not 
detected because they are situated outside of the zones usually studied (Dehainault et al., 
2007). They can also correspond to mosaics, which cannot be detected on circulating 
leukocytes (see “Notes” section). 
3.3.1.3 DNA methylation analysis 
Hypermethylation of the promoter region is a common mutational event found in tumor 
(Richter et al., 2003). Hypermethylation of the promoter are investigated by bisulfite analysis 
followed either by sequencing, by methylation-specific PCR or by a quantitative analysis of 
methylated allele using specific Taqman® probes (De La Rosa-Velazquez et al., 2007, Richter 
et al., 2003, Zeschnigk et al., 2004). Alternatively, tumor DNA can be digested using 
methylation sensitive enzyme (CfoI as an example), followed by PCR amplification of the 
promoter and agarose gel electrophoresis or followed by a semiquantitative technique such 
as QMPSF (Taylor et al., 2007).  
3.3.2 Indirect testing 
Indirect testing is based on amplification of polymorphic markers of the RB1 locus. Analysis 
of polymorphic genetic markers localized in and around the RB1 gene in an affected child 
and his parents is designed to identify the RB1 allele carrying or putatively carrying a 
predisposition to retinoblastoma. Indirect tests are very useful in familial cases, when 
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samples are available for at least two cases of retinoblastoma, to identify the allele of the RB1 
gene common to affected cases, i.e. to determine the allele that carries the mutation, even 
when the mutation has not been demonstrated directly. In non-familial forms, reconstitution 
of the affected child’s alleles reveals the two alleles putatively associated with an alteration 
of the RB1 gene. Tumour DNA studies (when available) reveal loss of an allele in 65% of 
cases and consequently allow identification of the remaining allele, i.e. potentially carrying a 
germline mutation. The indirect approach is technically simple and rapid, but nevertheless 
requires testing of the affected child, the parents, and possibly other relatives. 
3.3.3 Cytogenetic analysis 
Cytogenetic analysis comprises a standard karyotype and analysis of the RB1 gene by FISH 
or CGH-array. The development of molecular genetic studies has considerably limited the 
applications of cytogenetics and its only first-line indication is for karyotyping in a child 
with mental retardation or a malformative syndrome associated with retinoblastoma. 
However, it remains useful for the detection of translocations and mosaic deletions and can 
help to estimate the size of very large deletions. It therefore reveals certain rare situations.  
High density CGH array may be useful for fine mapping of deletion breakpoints in a context 
of a contiguous gene syndrome (Mitter et al., 2011) 
3.4 Notes 
3.4.1 General problems 
3.4.1.1 GC-rich regions 
The 5’ part of the RB1 gene (promoter and exon 1) is particularly rich in GC, which can 
make it difficult to analyse, for the detection of both point mutations and rearrangements. 
Due to the high degree of similarity of the amplified region, nonspecific intrastrand base 
pairing tends to occur during PCR, resulting in nonspecific PCR. Consequently, some teams 
do not analyse this region, which makes the analysis incomplete, as mutations of the 
promoter region and exon 1 have been well documented. We have resolved these problems 
by the addition of dimethylsulfoxyde (DMSO) to the reaction medium. 
3.4.1.2 Mosaics 
The existence of somatic mosaics in retinoblastoma raises a major problem for molecular 
diagnosis, as the mutant clone may be below the limit of detection of the technique used, or 
may even be absent from the cells studied. We have identified a deleterious RB1 mutation 
from a blood sample of an affected child in whom tumour material was not available. 
Surprisingly, this mutation was detected in a very small percentage (estimated at 10%) of 
buccal cells. DHPLC is particularly useful in this context because of its high sensitivity, but 
characterization of the anomaly by sequencing remains problematical and requires specific 
techniques (fraction collector, specific primers, cloning, etc.). 
3.4.1.3 Abnormalities of splicing 
Splicing abnormalities represent 20% of the mutational spectrum of RB1 and are therefore 
important to characterize. Unfortunately, the instability of messenger RNA carrying a 
premature stop codon means that the truncated messenger RNA is below the limit of 
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detection and only the wild-type transcript will be visible, wrongly suggesting the absence 
of an anomaly. This problem can sometimes be resolved by using translation inhibitors, 
such as puromycin, which eliminate NMD and therefore improve detection of the truncated 
messenger RNA (Andreutti-Zaugg et al., 1997). 
Some deep intronic anomalies, responsible for alternative splicing, are probably not detected 
because they are situated outside the zones routinely studied. Systematic RNA analysis 
would be required to demonstrate these anomalies. This approach, unsuitable for routine 
testing, is nevertheless used in the case of failure of other techniques in situations of highly 
probable predisposition, such as cases of bilateral and/or familial retinoblastoma with no 
identified mutation (Dehainault et al., 2007). 
3.4.2 Detection of point mutations by DHPLC 
DHPLC is a sensitive and reliable technique for the detection of point mutations. However, 
its efficacy is subject to the availability of specific, high-yield PCR and rigorous system 
quality control, as the gradient drift can impair the quality of testing by modifying retention 
times and, much more insidiously, loss of calibration, even minimal, of the oven can be 
responsible for a drastic reduction of resolution for certain amplicons, generating false-
negative results. It is therefore essential to ensure the integrity of the system each day by 
using control samples. Control samples should generate slight modifications of the profile, 
which can therefore only be detected with an optimally functioning system. The limitations 
of this method, which depend on the base composition of the DNA fragment studied, must 
be kept in mind. For example, despite all of our efforts, we have not been able to obtain 
reliable results for exon 8 of RB1, which must be sequenced as first-line procedure 
(Dehainault et al., 2004). This point has also been emphasized by P. Oefner, the inventor of 
DHPLC (Sivakumaran et al., 2005). 
3.4.3 Detection of chromosomal rearrangements by semiquantitative techniques 
MLPA or semiquantitative multiplex PCR techniques (such as QMPSF) are robust 
techniques, but highly dependent on the quality of the DNA studied. Degraded DNA will 
be responsible for loss of proportionality between signal intensity and copy number, 
particularly for large fragments, making the analysis uninterpretable. Contamination of 
DNA by phenol will have an even greater effect, because it generates a random fluctuation 
of signal intensity. Phenol-free extraction techniques should therefore be preferred 
(perchlorate/chloroform or column-based commercial kits) or a system ensuring the 
absence of contamination by phenol such as the gel lock extraction system, which uses a gel-
barrier system (Eppendorf®). 
It is also essential to adjust all DNA samples studied to a suitable working concentration, 
classically 50 ng/µl. If the DNA concentration is too high, for example, the proportionality 
between signal intensity and copy number will be lost, particularly for small fragments. 
DNA calibration can be performed with: i) a tube spectrophotometer (unsuitable for large 
series); ii) the NanoDrop from NanoDrop technologies (which has the advantage of tracing 
the spectrum of the sample); or iii) a plate reader (rapid, but reading at only one wavelength 
at a time). In our experience, the use of fluorescent dyes for the assay, such as PicoGreen 
(Molecular Probes), is unnecessary for these applications. 
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Finally, buccal swabs are poorly adapted to these analyses, including for the search of a 
mutation already identified in a relative, as DNA is often present in a low concentration and 
difficult to calibrate for FTA samples. 
Due to the importance of quality/quantity/calibration of DNA solutions, laboratories often 
prefer to extract DNA locally and therefore ask to receive whole blood. 
A classical trap in the interpretation of these techniques concerns the false-positive results 
generated by a PCR primer mismatch. Each deletion of a single exon must therefore be 
systematically checked by another technique and/or by shifting the primers (long range 
PCR, RNA studies, real-time PCR, for example). Finally, duplication of an isolated exon is 
the most difficult case to characterize. The ideal situation is therefore to have a duplicated 
control of the entire RB1, for example DNA from a case of trisomy 13. 
4. Conclusion 
Finally, we recommend a systematic RB1 molecular screening to all retinoblastoma patients as 
part of routine clinical care. Emphasis is placed on close collaboration between laboratory staff 
and clinicians to ensure effective communication and therefore adequate genetic counseling. 
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